Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Return on Assets (2021 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Return on Assets for 5 consecutive years, with 0.61% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Assets rose 243.0% to 0.61% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.61%, a 243.0% increase, with the full-year FY2024 number at 0.51%, up 51.0% from a year prior.
  • Return on Assets was 0.61% for Q3 2025 at Inhibikase Therapeutics, down from 0.48% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.23% in Q3 2021 to a low of 3.04% in Q3 2024.
  • A 5-year average of 0.82% and a median of 0.6% in 2022 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: crashed -204bps in 2024, then surged 243bps in 2025.
  • Inhibikase Therapeutics' Return on Assets stood at 0.33% in 2021, then tumbled by -102bps to 0.68% in 2022, then tumbled by -83bps to 1.24% in 2023, then soared by 55bps to 0.56% in 2024, then fell by -9bps to 0.61% in 2025.
  • Per Business Quant, the three most recent readings for IKT's Return on Assets are 0.61% (Q3 2025), 0.48% (Q2 2025), and 0.4% (Q1 2025).